AstraZeneca PLC (AZN)
| Market Cap | 213.42B |
| Revenue (ttm) | 54.07B |
| Net Income (ttm) | 7.04B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.50 |
| PE Ratio | 15.22 |
| Forward PE | 15.51 |
| Dividend | $1.54 (2.25%) |
| Ex-Dividend Date | Feb 21, 2025 |
| Volume | 5,997,733 |
| Open | 68.81 |
| Previous Close | 67.87 |
| Day's Range | 68.41 - 69.26 |
| 52-Week Range | 61.24 - 87.68 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 89.75 (+31.0%) |
| Earnings Date | Apr 29, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price forecast is $89.75, which is an increase of 31.00% from the latest price.
News
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collabora...
AstraZeneca CEO says Europe must protect its health sovereignty, is falling behind on pharma investments
AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that Europe has stepped up its defence spending and now must protect its health sovereignty amid a shifting world order.
AstraZeneca rejoins leading U.S. drug lobby group after two-year absence
AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and Manufacturers of America (PhRMA) said on Tuesday.
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Selling America, Buying Europe - My Picks
After years of strong returns, amidst the tariff-induced uncertainty, I am rotating towards European-based equities. US economy is facing mounting pressures, via weakening consumer demand, reduced CAP...
European pharma companies issue demands to stay in EU ahead of expected US tariffs
Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, inclu...
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squ...
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
AstraZeneca's Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy
AstraZeneca achieved record revenue growth of 18% in 2024, driven by key products like Farxiga and Tagrisso, and numerous regulatory approvals. The company's diversified portfolio spans oncology, CVRM...
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting. T...
Pharma stocks survive market rout on tariff exemption, but uncertainty continues
Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal tariffs, but executives and analysts warned it was premature to c...
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Pharma tariffs the 'number one question' on investors' minds, Barclays says
Emily Field, head of European pharmaceuticals research at Barclays, weighs in on the potential impact of U.S. tariffs on the pharmaceuticals sector.
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardio...
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, S...